Recombinant IL-@ reduced ( p < @ ) the aggravation of symptoms to @ days , neurological deficit ( @ EDSS scores at discharge from the hospital ) , frequency of exacerbations ( from @ to @ % ) and frequency of cases with the development of multiple sclerosis during @ years ( from @ to @ % ) .